Will Epicovid19's next result indicate a further decline in Covid-19 cases in Brazil?
Market Rules
Researchers from the Universidade Federal de Pelotas, in the Rio Grande do Sul, Brazil, have been working on a massive epidemiological study, called Epicovid19, to identify the prevalence of SARS-CoV-2 in the Brazilian population. In the previous 3 phases, they found an average of 1.9%, 3.1%, and 3.8% of Brazilians, respectively, had developed antibodies against the virus in the 45 days that preceeded the measurement, which could be interpreted as evidence of accelerating spread.
On the fourth phase of the study (August 2020), they found an average of 1.4% Brazilians with recently-developed antibodies. According to the researchers, this indicates that the epidemic is decelerating in Brazil, as fewer people are getting infected in a given timeframe.
If the results of the next phase of Epicovid indicate a new decline in antibody prevalence, this market will be resolved as "Yes".